465 related articles for article (PubMed ID: 27560183)
1. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
Jardine JG; Sok D; Julien JP; Briney B; Sarkar A; Liang CH; Scherer EA; Henry Dunand CJ; Adachi Y; Diwanji D; Hsueh J; Jones M; Kalyuzhniy O; Kubitz M; Spencer S; Pauthner M; Saye-Francisco KL; Sesterhenn F; Wilson PC; Galloway DM; Stanfield RL; Wilson IA; Burton DR; Schief WR
PLoS Pathog; 2016 Aug; 12(8):e1005815. PubMed ID: 27560183
[TBL] [Abstract][Full Text] [Related]
2. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.
Wiehe K; Bradley T; Meyerhoff RR; Hart C; Williams WB; Easterhoff D; Faison WJ; Kepler TB; Saunders KO; Alam SM; Bonsignori M; Haynes BF
Cell Host Microbe; 2018 Jun; 23(6):759-765.e6. PubMed ID: 29861171
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.
Jardine JG; Kulp DW; Havenar-Daughton C; Sarkar A; Briney B; Sok D; Sesterhenn F; Ereño-Orbea J; Kalyuzhniy O; Deresa I; Hu X; Spencer S; Jones M; Georgeson E; Adachi Y; Kubitz M; deCamp AC; Julien JP; Wilson IA; Burton DR; Crotty S; Schief WR
Science; 2016 Mar; 351(6280):1458-63. PubMed ID: 27013733
[TBL] [Abstract][Full Text] [Related]
4. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
5. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
McGuire AT
Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
[TBL] [Abstract][Full Text] [Related]
7. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.
Hwang JK; Wang C; Du Z; Meyers RM; Kepler TB; Neuberg D; Kwong PD; Mascola JR; Joyce MG; Bonsignori M; Haynes BF; Yeap LS; Alt FW
Proc Natl Acad Sci U S A; 2017 Aug; 114(32):8614-8619. PubMed ID: 28747530
[TBL] [Abstract][Full Text] [Related]
8. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
[TBL] [Abstract][Full Text] [Related]
9. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?
Medina-Ramírez M; Sanders RW; Klasse PJ
Expert Rev Vaccines; 2014 Apr; 13(4):449-52. PubMed ID: 24606603
[TBL] [Abstract][Full Text] [Related]
10. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
Landais E; Moore PL
Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
[TBL] [Abstract][Full Text] [Related]
11. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.
McGuire AT; Dreyer AM; Carbonetti S; Lippy A; Glenn J; Scheid JF; Mouquet H; Stamatatos L
Science; 2014 Dec; 346(6215):1380-1383. PubMed ID: 25504724
[TBL] [Abstract][Full Text] [Related]
12. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design.
Finney J; Kelsoe G
Retrovirology; 2018 Jul; 15(1):53. PubMed ID: 30055635
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.
Klein F; Diskin R; Scheid JF; Gaebler C; Mouquet H; Georgiev IS; Pancera M; Zhou T; Incesu RB; Fu BZ; Gnanapragasam PN; Oliveira TY; Seaman MS; Kwong PD; Bjorkman PJ; Nussenzweig MC
Cell; 2013 Mar; 153(1):126-38. PubMed ID: 23540694
[TBL] [Abstract][Full Text] [Related]
14. The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development.
Zhang Y; Yuan T; Li J; Zhang Y; Xu J; Shao Y; Chen Z; Zhang MY
AIDS; 2013 Oct; 27(16):2529-39. PubMed ID: 24100711
[TBL] [Abstract][Full Text] [Related]
15. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.
Andrabi R; Voss JE; Liang CH; Briney B; McCoy LE; Wu CY; Wong CH; Poignard P; Burton DR
Immunity; 2015 Nov; 43(5):959-73. PubMed ID: 26588781
[TBL] [Abstract][Full Text] [Related]
16. Polyreactivity and autoreactivity among HIV-1 antibodies.
Liu M; Yang G; Wiehe K; Nicely NI; Vandergrift NA; Rountree W; Bonsignori M; Alam SM; Gao J; Haynes BF; Kelsoe G
J Virol; 2015 Jan; 89(1):784-98. PubMed ID: 25355869
[TBL] [Abstract][Full Text] [Related]
17. Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.
Briney B; Sok D; Jardine JG; Kulp DW; Skog P; Menis S; Jacak R; Kalyuzhniy O; de Val N; Sesterhenn F; Le KM; Ramos A; Jones M; Saye-Francisco KL; Blane TR; Spencer S; Georgeson E; Hu X; Ozorowski G; Adachi Y; Kubitz M; Sarkar A; Wilson IA; Ward AB; Nemazee D; Burton DR; Schief WR
Cell; 2016 Sep; 166(6):1459-1470.e11. PubMed ID: 27610570
[TBL] [Abstract][Full Text] [Related]
18. Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.
Escolano A; Steichen JM; Dosenovic P; Kulp DW; Golijanin J; Sok D; Freund NT; Gitlin AD; Oliveira T; Araki T; Lowe S; Chen ST; Heinemann J; Yao KH; Georgeson E; Saye-Francisco KL; Gazumyan A; Adachi Y; Kubitz M; Burton DR; Schief WR; Nussenzweig MC
Cell; 2016 Sep; 166(6):1445-1458.e12. PubMed ID: 27610569
[TBL] [Abstract][Full Text] [Related]
19. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
Sacks D; Wiehe K; Morris L; Moore PL
J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865
[TBL] [Abstract][Full Text] [Related]
20. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
